Page last updated: 2024-10-25

cilostazol and Ischemia

cilostazol has been researched along with Ischemia in 50 studies

Ischemia: A hypoperfusion of the BLOOD through an organ or tissue caused by a PATHOLOGIC CONSTRICTION or obstruction of its BLOOD VESSELS, or an absence of BLOOD CIRCULATION.

Research Excerpts

ExcerptRelevanceReference
"To clarify the potential protective role of cilostazol on rat myocardial cells with ischemia-reperfusion injury (IRI) models."8.12Cardioprotective Effect of Cilostazol on Ischemia-Reperfusion Injury Model. ( Baytaroglu, C; Sahin, M; Sevgili, E, 2022)
" Cilostazol (CLZ) has pleiotropic effects including neuroprotection in several ravaging central disorders; nonetheless, its potential role in transient central ischemic-induced allodynia and hyperalgesia has not been asserted before."8.12Cilostazol Alleviates NLRP3 Inflammasome-Induced Allodynia/Hyperalgesia in Murine Cerebral Cortex Following Transient Ischemia: Focus on TRPA1/Glutamate and Akt/Dopamine/BDNF/Nrf2 Trajectories. ( Abdallah, DM; Mohammed, RA; Nassar, NN; Safar, MM; Zaki, OS, 2022)
"Cilostazol and L-carnitine have been used as a first-line drug and supplement, respectively, in patients with peripheral arterial disease with intermittent claudication."7.81Combination of Cilostazol and L-Carnitine Improves Walking Performance in Peripheral Arterial Disease Model Rats. ( Orito, K; Sahara, H; Shiga, T, 2015)
"The model of IR caused severe muscle injury in the rat hind limb and ischemic preconditioning has a protective effect, reducing myocyte necrosis, however, treatment with cilostazol and also the association between cilostazol and preconditioning has no protective effect on the skeletal muscle subjected to ischemia and reperfusion injury."7.80Effects of ischemic preconditioning and cilostazol on muscle ischemia-reperfusion injury in rats. ( Frias Neto, CA; Koike, MK; Montero, EF; Saad, KR; Saad, PF, 2014)
"We tested the hypothesis that clopidogrel and cilostazol combination therapy could effectively attenuate systemic inflammatory reaction, facilitate proliferation of circulating endothelial progenitor cell (EPC), and improve the clinical outcomes of critical limb ischemia (CLI) in patients unsuitable for surgical revascularization or percutaneous transluminal angioplasty (PTA)."7.80Levels and values of lipoprotein-associated phospholipase A2, galectin-3, RhoA/ROCK, and endothelial progenitor cells in critical limb ischemia: pharmaco-therapeutic role of cilostazol and clopidogrel combination therapy. ( Chai, HT; Chang, HW; Chen, CH; Chen, YC; Chen, YL; Chua, S; Chung, SY; Ko, SF; Leu, S; Lin, PY; Sheu, JJ; Sung, PH; Tsai, TH; Yip, HK, 2014)
"Cilostazol is effective for the treatment of peripheral ischemia."7.79Cilostazol improves the response to ischemia in diabetic mice by a mechanism dependent on PPARγ. ( Angelini, F; Arena, V; Biscetti, F; Ferraccioli, G; Flex, A; Ghirlanda, G; Pecorini, G; Stigliano, E, 2013)
"We studied ischemia-induced neovascularization in the ischemic hindlimb of cilostazol-treated and untreated control mice."7.79Cilostazol promotes angiogenesis after peripheral ischemia through a VEGF-dependent mechanism. ( Angelini, F; Arena, V; Biscetti, F; Flex, A; Ghirlanda, G; Locatelli, F; Pecorini, G; Rutella, S; Stigliano, E; Straface, G, 2013)
"To investigate the effect of cilostazol, in kidney and skeletal muscle of rats submitted to acute ischemia and reperfusion."7.78Effects of cilostazol in kidney and skeletal striated muscle of Wistar rats submitted to acute ischemia and reperfusion of hind limbs. ( Capelozzi, VL; Francisco Neto, A; Moreira Neto, AA; Parra-Cuentas, ER; Rodrigues, OR; Schmidt Júnior, AF; Souza Júnior, SS, 2012)
"Acetylcholine-and A23187-induced relaxation was reduced in the Ischemia/Reperfusion 120/90 group, and treatment with cilostazol partially prevented this ischemia/reperfusion-induced endothelium impairment."7.78The protective effect of cilostazol on isolated rabbit femoral arteries under conditions of ischemia and reperfusion: the role of the nitric oxide pathway. ( Capellini, VK; Celotto, AC; Evora, PR; Joviliano, EE; Piccinato, CE; Santos, MR, 2012)
"Combined cilostazol-clopidogrel therapy is superior to either agent alone in improving ischemia in rodent CLI."7.78Combination of cilostazol and clopidogrel attenuates rat critical limb ischemia. ( Chang, HW; Chen, YL; Chua, S; Leu, S; Lin, KC; Sheu, JJ; Sun, CK; Tsai, CY; Tsai, TH; Yang, JL; Yen, CH; Yip, HK, 2012)
" This study investigated whether cilostazol could improve the vasodilatory response of the brachial artery to ischemia, an indicator of endothelial function, in ten male smokers."7.72Effect of cilostazol on impaired vasodilatory response of the brachial artery to ischemia in smokers. ( Ebata, K; Kanehara, H; Miyamori, I; Oida, K; Suzuki, J, 2003)
"Cilostazol is a new phosphodiesterase inhibitor that suppresses platelet aggregation and also acts as a direct arterial vasodilator."6.69Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial. ( Cutler, BS; Dawson, DL; Meissner, MH; Strandness, DE, 1998)
"Cilostazol is a drug of choice for the treatment of intermittent claudication that also affects innate and adaptive immune cells."5.56Cilostazol Mediates Immune Responses and Affects Angiogenesis During the Acute Phase of Hind Limb Ischemia in a Mouse Model. ( Bouziotis, P; Kadoglou, NPE; Kakisis, I; Katsimpoulas, M; Kostomitsopoulos, NG; Kostopoulos, IV; Lazaris, A; Paronis, E; Poulaki, E; Prignon, A; Provost, C; Spyropoulos, C; Stasinopoulou, M; Tsitsilonis, O, 2020)
"Outcome measures were binary restenosis by angiogram, reocclusion, target lesion revascularization (TLR), limb salvage rate and complete wound healing at 3 months."5.38Impact of cilostazol on angiographic restenosis after balloon angioplasty for infrapopliteal artery disease in patients with critical limb ischemia. ( Hirano, K; Iida, O; Kawasaki, D; Soga, Y; Suzuki, K; Yamaoka, T, 2012)
"Cilostazol is a phosphodiesterase III inhibitor with a firm evidence base for use in intermittent claudication."5.35Cilostazol may improve outcome in critical limb ischemia. ( Davies, AH; Franklin, IJ; Shalhoub, J, 2009)
"Cilostazol (Pletal) was added to the medical regimen and at the 8-week follow-up the fourth and fifth fingers were warm with repeat plethysmography displaying normal perfusion."5.31Three cases of digital ischemia successfully treated with cilostazol. ( Dean, SM; Satiani, B, 2001)
" For patients with disabling intermittent claudication who do not respond to conservative measures and who are not candidates for surgical or catheter-based intervention, we suggest cilostazol (Grade 2A)."4.82Antithrombotic therapy in peripheral arterial occlusive disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. ( Clagett, GP; Jackson, MR; Lip, GY; Sobel, M; Tangelder, M; Verhaeghe, R, 2004)
" Cilostazol (CLZ) has pleiotropic effects including neuroprotection in several ravaging central disorders; nonetheless, its potential role in transient central ischemic-induced allodynia and hyperalgesia has not been asserted before."4.12Cilostazol Alleviates NLRP3 Inflammasome-Induced Allodynia/Hyperalgesia in Murine Cerebral Cortex Following Transient Ischemia: Focus on TRPA1/Glutamate and Akt/Dopamine/BDNF/Nrf2 Trajectories. ( Abdallah, DM; Mohammed, RA; Nassar, NN; Safar, MM; Zaki, OS, 2022)
"To clarify the potential protective role of cilostazol on rat myocardial cells with ischemia-reperfusion injury (IRI) models."4.12Cardioprotective Effect of Cilostazol on Ischemia-Reperfusion Injury Model. ( Baytaroglu, C; Sahin, M; Sevgili, E, 2022)
"The study was aimed at assessing efficacy and safety of treatment with Aducil® (cilostazol) compared with Trental® 400 in patients with moderate-to-severe intermittent claudication due to peripheral atherosclerosis."3.91[Clinical study of efficacy and safety of Aducil in patients with chronic lower limb ischaemia]. ( Chupin, AV; Gadzhimuradov, RU; Kalinin, RE; Kamaev, AA; Lar'kov, RN; Parshin, PI; Porsheneva, EV; Suchkov, IA; Uchkin, IG, 2019)
" Conservative treatment included: (a) weight-adjusted bemiparin plus six hours/day intravenous iloprost for 28 days, (b) aspirin (100 mg/day) plus cilostazol (100 mg twice/day) after discharge, and (c) strict recommendations/monitoring for smoking cessation."3.85Conservative treatment of patients with thromboangiitis obliterans or cannabis-associated arteritis presenting with critical lower limb ischaemia. ( Anastasiadou, C; Galyfos, G; Geropapas, G; Giannakakis, S; Kastrisios, G; Kerasidis, S; Maltezos, C; Papacharalampous, G; Papapetrou, A; Sachmpazidis, I, 2017)
"Cilostazol and L-carnitine have been used as a first-line drug and supplement, respectively, in patients with peripheral arterial disease with intermittent claudication."3.81Combination of Cilostazol and L-Carnitine Improves Walking Performance in Peripheral Arterial Disease Model Rats. ( Orito, K; Sahara, H; Shiga, T, 2015)
"The model of IR caused severe muscle injury in the rat hind limb and ischemic preconditioning has a protective effect, reducing myocyte necrosis, however, treatment with cilostazol and also the association between cilostazol and preconditioning has no protective effect on the skeletal muscle subjected to ischemia and reperfusion injury."3.80Effects of ischemic preconditioning and cilostazol on muscle ischemia-reperfusion injury in rats. ( Frias Neto, CA; Koike, MK; Montero, EF; Saad, KR; Saad, PF, 2014)
"We tested the hypothesis that clopidogrel and cilostazol combination therapy could effectively attenuate systemic inflammatory reaction, facilitate proliferation of circulating endothelial progenitor cell (EPC), and improve the clinical outcomes of critical limb ischemia (CLI) in patients unsuitable for surgical revascularization or percutaneous transluminal angioplasty (PTA)."3.80Levels and values of lipoprotein-associated phospholipase A2, galectin-3, RhoA/ROCK, and endothelial progenitor cells in critical limb ischemia: pharmaco-therapeutic role of cilostazol and clopidogrel combination therapy. ( Chai, HT; Chang, HW; Chen, CH; Chen, YC; Chen, YL; Chua, S; Chung, SY; Ko, SF; Leu, S; Lin, PY; Sheu, JJ; Sung, PH; Tsai, TH; Yip, HK, 2014)
"We studied ischemia-induced neovascularization in the ischemic hindlimb of cilostazol-treated and untreated control mice."3.79Cilostazol promotes angiogenesis after peripheral ischemia through a VEGF-dependent mechanism. ( Angelini, F; Arena, V; Biscetti, F; Flex, A; Ghirlanda, G; Locatelli, F; Pecorini, G; Rutella, S; Stigliano, E; Straface, G, 2013)
"Cilostazol is effective for the treatment of peripheral ischemia."3.79Cilostazol improves the response to ischemia in diabetic mice by a mechanism dependent on PPARγ. ( Angelini, F; Arena, V; Biscetti, F; Ferraccioli, G; Flex, A; Ghirlanda, G; Pecorini, G; Stigliano, E, 2013)
"An experimental study was designed using 30 Wistar rats divided into five groups (n = 6): control (C); ischemia (I) - animals submitted to left common iliac artery interruption without pharmacologic treatment; pentoxifylline (Pen) - rats submitted to procedure and treated with pentoxifylline 3 mg/kg twice a day for 6 weeks; cilostazol (Cil) - animals submitted to procedure and treated with cilostazol 30 mg/kg twice a day for 6 weeks; and sham (S) - animals submitted to procedure without artery interruption."3.78Effect of cilostazol and pentoxifylline on gait biomechanics in rats with ischemic left hindlimb. ( Bredarioli, M; Dalio, MB; do Prado, WA; Joviliano, EE; Piccinato, CE, 2012)
"Combined cilostazol-clopidogrel therapy is superior to either agent alone in improving ischemia in rodent CLI."3.78Combination of cilostazol and clopidogrel attenuates rat critical limb ischemia. ( Chang, HW; Chen, YL; Chua, S; Leu, S; Lin, KC; Sheu, JJ; Sun, CK; Tsai, CY; Tsai, TH; Yang, JL; Yen, CH; Yip, HK, 2012)
"To investigate the effect of cilostazol, in kidney and skeletal muscle of rats submitted to acute ischemia and reperfusion."3.78Effects of cilostazol in kidney and skeletal striated muscle of Wistar rats submitted to acute ischemia and reperfusion of hind limbs. ( Capelozzi, VL; Francisco Neto, A; Moreira Neto, AA; Parra-Cuentas, ER; Rodrigues, OR; Schmidt Júnior, AF; Souza Júnior, SS, 2012)
"Acetylcholine-and A23187-induced relaxation was reduced in the Ischemia/Reperfusion 120/90 group, and treatment with cilostazol partially prevented this ischemia/reperfusion-induced endothelium impairment."3.78The protective effect of cilostazol on isolated rabbit femoral arteries under conditions of ischemia and reperfusion: the role of the nitric oxide pathway. ( Capellini, VK; Celotto, AC; Evora, PR; Joviliano, EE; Piccinato, CE; Santos, MR, 2012)
"The present study demonstrates that cilostazol attenuates retinal injury after transient ischemia via inhibition of leukocyte-endothelial cell interactions."3.74Neuroprotective effect of cilostazol against retinal ischemic damage via inhibition of leukocyte-endothelial cell interactions. ( Iwama, D; Kiryu, J; Miyahara, S; Miyamoto, K; Tamura, H; Tsujikawa, A; Yamashiro, K; Yoshimura, N, 2007)
" This study investigated whether cilostazol could improve the vasodilatory response of the brachial artery to ischemia, an indicator of endothelial function, in ten male smokers."3.72Effect of cilostazol on impaired vasodilatory response of the brachial artery to ischemia in smokers. ( Ebata, K; Kanehara, H; Miyamori, I; Oida, K; Suzuki, J, 2003)
"Cilostazol did not increase the ABI but caused a significant increase in the SPP from 24."2.76Cilostazol increases skin perfusion pressure in severely ischemic limbs. ( Iida, O; Miyamoto, A; Miyashita, Y; Nanto, S; Saito, S, 2011)
"Cilostazol treatment also increased freedom from target lesion revascularization (RR, 1."2.72Literature review and meta-analysis of the efficacy of cilostazol on limb salvage rates after infrainguinal endovascular and open revascularization. ( Desai, K; Han, B; Kuziez, L; Yan, Y; Zayed, MA, 2021)
"Cilostazol is a new phosphodiesterase inhibitor that suppresses platelet aggregation and also acts as a direct arterial vasodilator."2.69Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial. ( Cutler, BS; Dawson, DL; Meissner, MH; Strandness, DE, 1998)
"In the peripheral arteries, a thrombus superimposed on atherosclerosis contributes to the progression of peripheral artery disease (PAD), producing intermittent claudication (IC), ischemic necrosis, and, potentially, loss of the limb."2.50Systematic reviews and meta-analyses for more profitable strategies in peripheral artery disease. ( Cafaro, G; de Gaetano, G; Di Minno, A; Di Minno, G; Lupoli, R; Petitto, M; Spadarella, G; Tremoli, E, 2014)
"The key areas of treatment focus on smoking cessation, exercise rehabilitation, with supervised therapy if possible, cardiovascular risk prevention with antiplatelet drugs, statins and angiotensin converting enzymes, and correction of atherosclerotic risk factors with well-defined targets (LDL less than 1g/L, HDL greater than 0."2.45[Peripheral arterial disease with lower limb claudication: Medical treatment]. ( Bui, HT; Hadj Henni, A; Journet, J; Long, A, 2009)
"Cilostazol is a drug of choice for the treatment of intermittent claudication that also affects innate and adaptive immune cells."1.56Cilostazol Mediates Immune Responses and Affects Angiogenesis During the Acute Phase of Hind Limb Ischemia in a Mouse Model. ( Bouziotis, P; Kadoglou, NPE; Kakisis, I; Katsimpoulas, M; Kostomitsopoulos, NG; Kostopoulos, IV; Lazaris, A; Paronis, E; Poulaki, E; Prignon, A; Provost, C; Spyropoulos, C; Stasinopoulou, M; Tsitsilonis, O, 2020)
"Ergotism is an ischaemic complication due to vasoconstriction throughout the body due to ingestion of ergotamine."1.48Headache in an HIV-Positive Patient: Dangerous Interaction. ( Garner, O; Iardino, A; Lorusso, G; Lotta, F, 2018)
"Cilostazol is an antiplatelet agent with vasodilatory effects that works by increasing intracellular concentrations of cyclic adenosine monophosphate (cAMP)."1.43Cilostazol improves high glucose-induced impaired angiogenesis in human endothelial progenitor cells and vascular endothelial cells as well as enhances vasculoangiogenesis in hyperglycemic mice mediated by the adenosine monophosphate-activated protein kin ( Chao, TH; Chen, JH; Cho, CL; Lee, CH; Li, YH; Liu, PY; Tseng, SY; Wu, HL, 2016)
"Cilostazol has been shown to be beneficial for the improvement of pain-free walking distance in patients with intermittent claudication in a series of randomized clinical trials."1.43Induction of Angiogenesis by a Type III Phosphodiesterase Inhibitor, Cilostazol, Through Activation of Peroxisome Proliferator-Activated Receptor-γ and cAMP Pathways in Vascular Cells. ( Carracedo, M; Ikeda-Iwabu, Y; Kanbara, Y; Morishita, R; Muratsu, J; Otsu, R; Rakugi, H; Sanada, F; Sugimoto, K; Taniyama, Y; Yamamoto, K, 2016)
"Cilostazol treatment may be useful for the management of diabetic retinal vascular dysfunction and neuronal degeneration."1.39Neuroprotective effects of cilostazol on retinal ganglion cell damage in diabetic rats. ( Jung, KI; Kim, JH; Park, CK; Park, HY, 2013)
"Cilostazol is known to be a selective inhibitor of phosphodiesterase 3 and is generally used to treat intermittent claudication caused by peripheral arterial disease."1.38Cilostazol stimulates revascularisation in response to ischaemia via an eNOS-dependent mechanism. ( Hori, A; Komori, K; Morisaki, K; Murohara, T; Shibata, R, 2012)
"Cilostazol is an anti-platelet agent with vasodilatory activity that acts by increasing intracellular concentrations of cAMP."1.38A novel vasculo-angiogenic effect of cilostazol mediated by cross-talk between multiple signalling pathways including the ERK/p38 MAPK signalling transduction cascade. ( Chao, TH; Chen, JH; Cho, CL; Li, YH; Liu, PY; Shi, GY; Tseng, SY; Wu, HL, 2012)
"Outcome measures were binary restenosis by angiogram, reocclusion, target lesion revascularization (TLR), limb salvage rate and complete wound healing at 3 months."1.38Impact of cilostazol on angiographic restenosis after balloon angioplasty for infrapopliteal artery disease in patients with critical limb ischemia. ( Hirano, K; Iida, O; Kawasaki, D; Soga, Y; Suzuki, K; Yamaoka, T, 2012)
"Cilostazol is a phosphodiesterase III inhibitor with a firm evidence base for use in intermittent claudication."1.35Cilostazol may improve outcome in critical limb ischemia. ( Davies, AH; Franklin, IJ; Shalhoub, J, 2009)

Research

Studies (50)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (2.00)18.2507
2000's9 (18.00)29.6817
2010's33 (66.00)24.3611
2020's7 (14.00)2.80

Authors

AuthorsStudies
Sahin, M1
Baytaroglu, C1
Sevgili, E1
Zaki, OS1
Nassar, NN1
Abdallah, DM1
Safar, MM1
Mohammed, RA1
Tseng, SY4
Chang, HY2
Li, YH4
Chao, TH4
Suchkov, IA1
Kalinin, RE1
Gadzhimuradov, RU1
Lar'kov, RN1
Uchkin, IG1
Chupin, AV1
Parshin, PI1
Kamaev, AA1
Porsheneva, EV1
Paronis, E1
Katsimpoulas, M1
Kadoglou, NPE1
Provost, C1
Stasinopoulou, M1
Spyropoulos, C1
Poulaki, E1
Prignon, A1
Kakisis, I1
Kostomitsopoulos, NG1
Bouziotis, P1
Kostopoulos, IV1
Tsitsilonis, O1
Lazaris, A1
Desai, K1
Han, B1
Kuziez, L1
Yan, Y1
Zayed, MA1
Lee, CY1
Wu, TC1
Lin, SJ1
Shimatani, K1
Sato, H1
Saito, A1
Sasai, M1
Watanabe, K1
Mizukami, K1
Kamohara, M1
Miyagawa, S1
Sawa, Y1
Soga, Y3
Takahara, M1
Iida, O4
Yamauchi, Y1
Hirano, K3
Fukunaga, M1
Zen, K1
Suzuki, K3
Shintani, Y1
Miyashita, Y3
Tsuchiya, T2
Yamaoka, T2
Ando, K1
Galyfos, G1
Kerasidis, S1
Kastrisios, G1
Giannakakis, S1
Sachmpazidis, I1
Anastasiadou, C1
Geropapas, G1
Papapetrou, A1
Papacharalampous, G1
Maltezos, C1
Wang, Z1
Liu, T1
Chen, X1
You, H1
Zhang, Q1
Xue, J1
Zheng, Y1
Luo, D1
Mii, S1
Guntani, A1
Kawakubo, E1
Tanaka, K1
Kyuragi, R2
Iardino, A1
Garner, O1
Lorusso, G1
Lotta, F1
Coelho da Mota, DS1
Sicuro, FL1
Resende, AC1
De Moura, RS1
Bottino, DA1
Bouskela, E1
Furuyama, T1
Onohara, T1
Yamashita, S1
Yoshiga, R1
Yoshiya, K1
Inoue, K1
Morisaki, K2
Matsumoto, T1
Maehara, Y1
Kan, CD1
Wang, JN1
Li, WP1
Lin, SH1
Chen, WL1
Hsu, YP1
Yeh, CS1
Jung, KI1
Kim, JH1
Park, HY1
Park, CK1
Biscetti, F3
Pecorini, G2
Arena, V2
Stigliano, E2
Angelini, F2
Ghirlanda, G2
Ferraccioli, G2
Flex, A3
Sheu, JJ2
Lin, PY1
Sung, PH1
Chen, YC1
Leu, S2
Chen, YL2
Tsai, TH2
Chai, HT1
Chua, S2
Chang, HW2
Chung, SY1
Chen, CH1
Ko, SF1
Yip, HK2
Spiliopoulos, S1
Di Minno, G1
Spadarella, G1
Cafaro, G1
Petitto, M1
Lupoli, R1
Di Minno, A1
de Gaetano, G1
Tremoli, E1
Azarbal, A1
Clavijo, L1
Gaglia, MA1
Frias Neto, CA1
Koike, MK1
Saad, KR1
Saad, PF1
Montero, EF1
Liu, PY2
Lee, CH1
Cho, CL2
Wu, HL2
Chen, JH2
Shiga, T1
Sahara, H1
Orito, K1
Sanada, F1
Kanbara, Y1
Taniyama, Y1
Otsu, R1
Carracedo, M1
Ikeda-Iwabu, Y1
Muratsu, J1
Sugimoto, K1
Yamamoto, K1
Rakugi, H1
Morishita, R1
Long, A1
Bui, HT1
Journet, J1
Hadj Henni, A1
Shalhoub, J1
Davies, AH1
Franklin, IJ1
Saito, S1
Miyamoto, A1
Nanto, S1
Hwang, SJ1
Jeong, YH1
Kim, IS1
Park, KS1
Kang, MK1
Koh, JS1
Park, JR1
Park, Y1
Koh, EH1
Kwak, CH1
Hwang, JY1
Kim, S1
Kwon, SU1
Hong, KS1
Kang, DW1
Park, JM1
Lee, JH1
Cho, YJ1
Yu, KH1
Koo, JS1
Wong, KS1
Lee, SH1
Lee, KB1
Kim, DE1
Jeong, SW1
Bae, HJ1
Lee, BC1
Han, MK1
Rha, JH1
Kim, HY1
Mok, VC1
Lee, YS1
Kim, GM1
Suwanwela, NC1
Yun, SC1
Nah, HW1
Kim, JS1
Hori, A1
Shibata, R1
Murohara, T1
Komori, K1
Kawasaki, D2
Nobuyoshi, M1
Shi, GY1
Santos, MR1
Celotto, AC1
Capellini, VK1
Evora, PR1
Piccinato, CE2
Joviliano, EE2
Straface, G1
Rutella, S1
Locatelli, F1
Bredarioli, M1
Dalio, MB1
do Prado, WA1
Garimella, PS1
Hart, PD1
O'Hare, A1
DeLoach, S1
Herzog, CA1
Hirsch, AT1
Lin, KC1
Tsai, CY1
Yen, CH1
Sun, CK1
Yang, JL1
Moreira Neto, AA1
Souza Júnior, SS1
Capelozzi, VL1
Parra-Cuentas, ER1
Schmidt Júnior, AF1
Francisco Neto, A1
Rodrigues, OR1
Oida, K1
Ebata, K1
Kanehara, H1
Suzuki, J1
Miyamori, I1
Stapanavatr, W1
Ungkittpaiboon, W1
Karnjanabatr, B1
Clagett, GP1
Sobel, M1
Jackson, MR1
Lip, GY1
Tangelder, M1
Verhaeghe, R1
Iwama, D1
Miyamoto, K1
Miyahara, S1
Tamura, H1
Tsujikawa, A1
Yamashiro, K1
Kiryu, J1
Yoshimura, N1
Dawson, DL1
Cutler, BS1
Meissner, MH1
Strandness, DE1
Mohler, ER1
Beebe, HG1
Salles-Cuhna, S1
Zimet, R1
Zhang, P1
Heckman, J1
Forbes, WP1
Hiatt, WR1
Nehler, MR1
Dean, SM1
Satiani, B1

Clinical Trials (7)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Study of the Efficacy and Safety of Cilostazol in the Prevention of Ischemic Vascular Events in Diabetic Patients With Symptomatic Peripheral Artery Disease.[NCT02983214]Phase 4826 participants (Actual)Interventional2016-11-30Completed
CYP 2C19 Polymorphism and Response to Adjunctive Cilostazol and High Maintenance-dose Clopidogrel in Patients Undergoing Elective Percutaneous Coronary Intervention[NCT01012193]Phase 4134 participants (Actual)Interventional2008-01-31Completed
Trial for Efficacy and Safety of Cilostazol on the Progression of Symptomatic Intracranial Stenosis Comparing Clopidogrel[NCT00130039]Phase 4457 participants (Actual)Interventional2005-08-31Completed
Cilostazol Enhances the Number and Functions of Circulating Endothelial Progenitor Cells and Collateral Formation Assessed by Dual-energy 128-row CT Angiography Mediated Through Multiple Mechanisms in Patients With Mild-to-moderate PAOD[NCT01952756]Phase 444 participants (Actual)Interventional2012-01-31Completed
Cilostazol Enhances the Number and Functions of Circulating Endothelial Progenitor Cells and Endothelial Function Mediated Through Modification of Vasculogenesis and Angiogenesis Factors in Patients With Stable Coronary Artery Disease[NCT02174939]Phase 4300 participants (Anticipated)Interventional2014-02-28Recruiting
Cilostazol Enhances the Number and Functions of Circulating Endothelial Progenitor Cells Mediated Through Multiple Mechanisms in Patients With High Risk for Cardiovascular Disease[NCT02194686]Phase 471 participants (Actual)Interventional2013-01-31Completed
Evaluation of Cilostazol in Combination With L-Carnitine in Subjects With Intermittent Claudication[NCT00822172]Phase 4164 participants (Actual)Interventional2008-09-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Number of Participants With New MRI (Magnetic Resonance Image) Lesions on Follow-up MRI

number of patients with new ischemic lesions on FLAIR (Fluid attenuation inversion recovery) images of follow-up MRI, which were determined by slice to slice comparison with baseline MRI. (NCT00130039)
Timeframe: 7 months after treatment

Interventionpariticipants (Number)
Cilostazol34
Clopidogrel23

Number of Participants With Overall Cardiovascular Events

including nonfatal stroke, nonfatal myocardial infarction and vascular death. (NCT00130039)
Timeframe: upto 7 months after randomization

Interventionparticipants (Number)
Cilostazol15
Clopidogrel10

Number of Participants With Progression of Symptomatic Intracranial Stenosis

"Blind reviewers classified the presence and severity of stenosis on middle cerebral arteries and basilar artery on magnetic resonance angiogram (MRA) into 5 grades; normal, mild, moderate, severe and occlusion. Progression was defined as worsening of stenosis by 1 or more grades on final MRA as compared with the baseline MRA.~The progression of symptomatic stenosis is defined as 1 or more grade worsening of the stenosis on the symptomatic artery on MRA." (NCT00130039)
Timeframe: 7 months after treatment

Interventionparticipants (Number)
Cilostazol20
Clopidogrel32

Number of Participants With Stroke Events

including nonfatal ischemic stroke, nonfatal hemorrhagic stroke and fatal stroke (NCT00130039)
Timeframe: upto 7 months after randomization

Interventionparticipants (Number)
Cilostazol11
Clopidogrel7

Number of Patients With Ipsilateral Ischemic Stroke Rate

ischemic stroke event which occured in the vascular territory of initial symptomatic stenosis (NCT00130039)
Timeframe: upto 7 months after randomization

Interventionparticipants (Number)
Cilostazol9
Clopidogrel5

Numbers of Fatal or Major Bleeding Complications

life-threatening or fatal bleeding was defined as any fatal bleeding event, a drop in hemoglobin of ≥ 50g/L, or significant hypotension with need for inotropic agents, symptomatic intracranial hemorrhage, or transfusion of ≥ 4 units of red-blood cells or equivalent amount of whole blood. Major bleeding was defined as significantly disabling bleedings, intraocular bleeding leading to significant visual loss, or bleeding requiring transfusion of ≤ 3 units of red-blood cells or equivalent amount of whole blood (NCT00130039)
Timeframe: upto 7 months after randomization

Interventionevents (Number)
Cilostazol2
Clopidogrel6

Change From Baseline in Claudication Onset Time at Day 180

Subjects were asked to complete a standardized exercise treadmill test using a modified Gardner protocol. Subjects walked on the treadmill until they were physically unable to walk further either as a result of their peripheral artery disease (PAD) symptoms or other non-PAD symptoms. The time during the conduct of the exercise treadmill test at which the subject first reported claudication symptoms is referred to as the claudication onset time (COT) and reported in minutes/seconds. The exercise treadmill test was conducted at Screening, Baseline, Day 90, and Day 180 visits. The log transformation is used to make highly skewed distributions less skewed. (NCT00822172)
Timeframe: Baseline, Day 180

InterventionLog Minutes (Mean)
Cilostazol + L-Carnitine1.065
Cilostazol + Placebo0.896

Change From Baseline in Claudication Onset Time at Day 90

Subjects were asked to complete a standardized exercise treadmill test using a modified Gardner protocol. Subjects walked on the treadmill until they were physically unable to walk further either as a result of their peripheral artery disease (PAD) symptoms or other non-PAD symptoms. The time during the conduct of the exercise treadmill test at which the subject first reported claudication symptoms is referred to as the claudication onset time (COT) and reported in minutes/seconds. The exercise treadmill test was conducted at Screening, Baseline, Day 90, and Day 180 visits. The log transformation is used to make highly skewed distributions less skewed. (NCT00822172)
Timeframe: Baseline, Day 90

InterventionLog Minutes (Mean)
Cilostazol + L-Carnitine1.001
Cilostazol + Placebo0.815

Change From Baseline in Peak Walking Time (PWT) at Day 180

Subjects were asked to complete a standardized exercise treadmill test using a modified Gardner protocol. Subjects walked on the treadmill until they were physically unable to walk further either as a result of their peripheral artery disease (PAD) symptoms or other non-PAD symptoms. This maximum time walked is referred to as the peak walking time (PWT) and reported in minutes/seconds. The exercise treadmill test was conducted at Screening, Baseline, Day 90, and Day 180 visits. The log transformation is used to make highly skewed distributions less skewed. (NCT00822172)
Timeframe: Baseline, Day 180

InterventionLog Minutes (Mean)
Cilostazol + L-Carnitine0.241
Cilostazol + Placebo0.134

Change From Baseline in Peak Walking Time at Day 180

Subjects were asked to complete a standardized exercise treadmill test using a modified Gardner protocol. Subjects walked on the treadmill until they were physically unable to walk further either as a result of their peripheral artery disease (PAD) symptoms or other non-PAD symptoms. This maximum time walked is referred to as the peak walking time (PWT) and reported in minutes/seconds. The exercise treadmill test was conducted at Screening, Baseline, Day 90, and Day 180 visits. The log transformation is used to make highly skewed distributions less skewed. (NCT00822172)
Timeframe: Baseline, Day 180

InterventionLog Minutes (Mean)
Cilostazol + L-Carnitine0.267
Cilostazol + Placebo0.145

Change From Baseline in Peak Walking Time at Day 90

Subjects were asked to complete a standardized exercise treadmill test using a modified Gardner protocol. Subjects walked on the treadmill until they were physically unable to walk further either as a result of their peripheral artery disease (PAD) symptoms or other non-PAD symptoms. This maximum time walked is referred to as the peak walking time (PWT) and reported in minutes/seconds. The exercise treadmill test was conducted at Screening, Baseline, Day 90, and Day 180 visits. The log transformation is used to make highly skewed distributions less skewed. (NCT00822172)
Timeframe: Baseline, Day 90

InterventionLog Minutes (Mean)
Cilostazol + L-Carnitine0.166
Cilostazol + Placebo0.139

Change From Baseline in Walking Impairment Questionnaire for Walking Distance at Day 180

Subjects completed the Walking Impairment Questionnaire (WIQ) whereby they were asked about their maximal walking distance before having to rest as a result of claudication symptoms associated with their peripheral artery disease (PAD). The WIQ was administered at the Baseline, Day 90, and Day 180 visits. On the WIQ subjects were asked a series of questions related to their degree of physical difficulty that best described how hard it was for the subject to walk on level ground without stopping to rest. The questions began by asking the degree of difficulty walking around indoors, then 50 feet, 150 feet, 300 feet, 600 feet, 900 feet, and lastly 1500 feet. The responses range from None (best outcome) to Slight, then Some, then Much, then lastly Unable (worst outcome). The walking distance score was calculated from the 7 questions in the section by way of a weighted sum. A score of 100 indicated no walking impairment. A score of 0 corresponded to the highest degree of walking impairment (NCT00822172)
Timeframe: Baseline, Day 180

Interventionscore on a scale (Mean)
Cilostazol + L-Carnitine13.20
Cilostazol + Placebo6.57

Change From Baseline in Walking Impairment Questionnaire for Walking Distance at Day 90

Subjects completed the Walking Impairment Questionnaire (WIQ) whereby they were asked about their maximal walking distance before having to rest as a result of claudication symptoms associated with their peripheral artery disease (PAD). The WIQ was administered at the Baseline, Day 90, and Day 180 visits. On the WIQ subjects were asked a series of questions related to their degree of physical difficulty that best described how hard it was for the subject to walk on level ground without stopping to rest. The questions began by asking the degree of difficulty walking around indoors, then 50 feet, 150 feet, 300 feet, 600 feet, 900 feet, and lastly 1500 feet. The responses range from None (best outcome) to Slight, then Some, then Much, then lastly Unable (worst outcome). The walking distance score was calculated from the 7 questions in the section by way of a weighted sum. A score of 100 indicated no walking impairment. A score of 0 corresponded to the highest degree of walking impairment (NCT00822172)
Timeframe: Baseline, Day 90

Interventionscore on a scale (Mean)
Cilostazol + L-Carnitine12.98
Cilostazol + Placebo10.01

Reviews

9 reviews available for cilostazol and Ischemia

ArticleYear
Literature review and meta-analysis of the efficacy of cilostazol on limb salvage rates after infrainguinal endovascular and open revascularization.
    Journal of vascular surgery, 2021, Volume: 73, Issue:2

    Topics: Aged; Aged, 80 and over; Amputation, Surgical; Cilostazol; Critical Illness; Endovascular Procedures

2021
Antiplatelet therapy in critical limb ischemia: update on clopidogrel and cilostazol.
    The Journal of cardiovascular surgery, 2014, Volume: 55, Issue:5

    Topics: Cilostazol; Clopidogrel; Combined Modality Therapy; Critical Illness; Drug Therapy, Combination; End

2014
Systematic reviews and meta-analyses for more profitable strategies in peripheral artery disease.
    Annals of medicine, 2014, Volume: 46, Issue:7

    Topics: Adenosine; Aspirin; Asymptomatic Diseases; Cilostazol; Clopidogrel; Fibrinolytic Agents; Humans; Int

2014
Antiplatelet therapy for peripheral arterial disease and critical limb ischemia: guidelines abound, but where are the data?
    Journal of cardiovascular pharmacology and therapeutics, 2015, Volume: 20, Issue:2

    Topics: Aspirin; Cilostazol; Dipyridamole; Endovascular Procedures; Extremities; Humans; Ischemia; Periphera

2015
New therapeutic effects of cilostazol in patients with ischemic disorders.
    Current vascular pharmacology, 2015, Volume: 13, Issue:3

    Topics: Cilostazol; Humans; Ischemia; Tetrazoles; Vasodilator Agents

2015
[Peripheral arterial disease with lower limb claudication: Medical treatment].
    Journal des maladies vasculaires, 2009, Volume: 34, Issue:5

    Topics: Aged; Antihypertensive Agents; Arteriosclerosis; Cilostazol; Comorbidity; Diabetes Complications; Dr

2009
Peripheral artery disease and CKD: a focus on peripheral artery disease as a critical component of CKD care.
    American journal of kidney diseases : the official journal of the National Kidney Foundation, 2012, Volume: 60, Issue:4

    Topics: Amputation, Surgical; Ankle Brachial Index; Atherosclerosis; Cilostazol; Diabetic Foot; Exercise The

2012
Antithrombotic therapy in peripheral arterial occlusive disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
    Chest, 2004, Volume: 126, Issue:3 Suppl

    Topics: Arterial Occlusive Diseases; Aspirin; Cilostazol; Clopidogrel; Contraindications; Evidence-Based Med

2004
Peripheral arterial disease.
    Advances in internal medicine, 2001, Volume: 47

    Topics: Angiotensin-Converting Enzyme Inhibitors; Cilostazol; Diabetes Complications; Diabetes Mellitus; Dis

2001

Trials

7 trials available for cilostazol and Ischemia

ArticleYear
Effects of Postoperative Percutaneous Coronary Intervention, Pharmacologic Treatment, and Predisposing Factors on Clinical Outcomes in Patients With and Without Type 2 Diabetes Along With Critical Limb Ischemia.
    Clinical therapeutics, 2021, Volume: 43, Issue:1

    Topics: Aged; Aged, 80 and over; Amputation, Surgical; Cilostazol; Diabetes Mellitus, Type 2; Extremities; F

2021
Efficacy of CilostAzol for Below-the-Knee Artery Disease after Balloon AnGioplasty in PatiEnts with Severe Limb Ischemia (CABBAGE Trial).
    Annals of vascular surgery, 2017, Volume: 45

    Topics: Aged; Aged, 80 and over; Amputation, Surgical; Angiography; Angioplasty, Balloon; Cardiovascular Age

2017
Cilostazol increases skin perfusion pressure in severely ischemic limbs.
    Angiology, 2011, Volume: 62, Issue:1

    Topics: Aged; Blood Pressure; Cilostazol; Extremities; Female; Humans; Ischemia; Male; Prospective Studies;

2011
Cytochrome 2C19 polymorphism and response to adjunctive cilostazol versus high maintenance-dose clopidogrel in patients undergoing percutaneous coronary intervention.
    Circulation. Cardiovascular interventions, 2010, Volume: 3, Issue:5

    Topics: Adenosine Diphosphate; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Blood Platelet

2010
Efficacy and safety of combination antiplatelet therapies in patients with symptomatic intracranial atherosclerotic stenosis.
    Stroke, 2011, Volume: 42, Issue:10

    Topics: Aged; Aged, 80 and over; Cilostazol; Clopidogrel; Constriction, Pathologic; Disease Progression; Dou

2011
Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial.
    Circulation, 1998, Aug-18, Volume: 98, Issue:7

    Topics: Adult; Aged; Arteriosclerosis; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cilostazol; Double-B

1998
Effects of cilostazol on resting ankle pressures and exercise-induced ischemia in patients with intermittent claudication.
    Vascular medicine (London, England), 2001, Volume: 6, Issue:3

    Topics: Aged; Ankle; Blood Pressure; Brachial Artery; Cilostazol; Double-Blind Method; Exercise; Female; Hem

2001

Other Studies

34 other studies available for cilostazol and Ischemia

ArticleYear
Cardioprotective Effect of Cilostazol on Ischemia-Reperfusion Injury Model.
    Brazilian journal of cardiovascular surgery, 2022, 12-01, Volume: 37, Issue:6

    Topics: Adenosine Triphosphate; Animals; Cilostazol; Disease Models, Animal; Ischemia; Rats; Rats, Wistar; R

2022
Cilostazol Alleviates NLRP3 Inflammasome-Induced Allodynia/Hyperalgesia in Murine Cerebral Cortex Following Transient Ischemia: Focus on TRPA1/Glutamate and Akt/Dopamine/BDNF/Nrf2 Trajectories.
    Molecular neurobiology, 2022, Volume: 59, Issue:12

    Topics: Animals; Brain Ischemia; Brain-Derived Neurotrophic Factor; Carrier Proteins; Cerebral Cortex; Cilos

2022
Effects of Cilostazol on Angiogenesis in Diabetes through Adiponectin/Adiponectin Receptors/Sirtuin1 Signaling Pathway.
    International journal of molecular sciences, 2022, Nov-27, Volume: 23, Issue:23

    Topics: Acetyl-CoA Carboxylase; Adiponectin; AMP-Activated Protein Kinases; Animals; Cilostazol; Diabetes Me

2022
Effects of Cilostazol on Angiogenesis in Diabetes through Adiponectin/Adiponectin Receptors/Sirtuin1 Signaling Pathway.
    International journal of molecular sciences, 2022, Nov-27, Volume: 23, Issue:23

    Topics: Acetyl-CoA Carboxylase; Adiponectin; AMP-Activated Protein Kinases; Animals; Cilostazol; Diabetes Me

2022
Effects of Cilostazol on Angiogenesis in Diabetes through Adiponectin/Adiponectin Receptors/Sirtuin1 Signaling Pathway.
    International journal of molecular sciences, 2022, Nov-27, Volume: 23, Issue:23

    Topics: Acetyl-CoA Carboxylase; Adiponectin; AMP-Activated Protein Kinases; Animals; Cilostazol; Diabetes Me

2022
Effects of Cilostazol on Angiogenesis in Diabetes through Adiponectin/Adiponectin Receptors/Sirtuin1 Signaling Pathway.
    International journal of molecular sciences, 2022, Nov-27, Volume: 23, Issue:23

    Topics: Acetyl-CoA Carboxylase; Adiponectin; AMP-Activated Protein Kinases; Animals; Cilostazol; Diabetes Me

2022
[Clinical study of efficacy and safety of Aducil in patients with chronic lower limb ischaemia].
    Angiologiia i sosudistaia khirurgiia = Angiology and vascular surgery, 2019, Volume: 25, Issue:3

    Topics: Cilostazol; Humans; Intermittent Claudication; Ischemia; Lower Extremity; Platelet Aggregation Inhib

2019
Cilostazol Mediates Immune Responses and Affects Angiogenesis During the Acute Phase of Hind Limb Ischemia in a Mouse Model.
    Journal of cardiovascular pharmacology and therapeutics, 2020, Volume: 25, Issue:3

    Topics: Angiogenesis Inducing Agents; Animals; Cilostazol; Cytokines; Disease Models, Animal; Hindlimb; Immu

2020
A novel model of chronic limb ischemia to therapeutically evaluate the angiogenic effects of drug candidates.
    American journal of physiology. Heart and circulatory physiology, 2021, 03-01, Volume: 320, Issue:3

    Topics: Angiogenesis Inducing Agents; Animals; Blood Flow Velocity; Cells, Cultured; Chronic Disease; Cilost

2021
Conservative treatment of patients with thromboangiitis obliterans or cannabis-associated arteritis presenting with critical lower limb ischaemia.
    VASA. Zeitschrift fur Gefasskrankheiten, 2017, Volume: 46, Issue:6

    Topics: Adult; Amputation, Surgical; Ankle Brachial Index; Anticoagulants; Arteritis; Aspirin; Cardiovascula

2017
Low molecular weight fucoidan ameliorates hindlimb ischemic injury in type 2 diabetic rats.
    Journal of ethnopharmacology, 2018, Jan-10, Volume: 210

    Topics: Animals; Cilostazol; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dose-Response Relat

2018
Cilostazol Improves Wound Healing in Patients Undergoing Open Bypass for Ischemic Tissue Loss: A Propensity Score Matching Analysis.
    Annals of vascular surgery, 2018, Volume: 49

    Topics: Adult; Aged; Aged, 80 and over; Arteriosclerosis Obliterans; Blood Vessel Prosthesis Implantation; C

2018
Headache in an HIV-Positive Patient: Dangerous Interaction.
    BMJ case reports, 2018, Jun-04, Volume: 2018

    Topics: Adult; Anti-HIV Agents; Anticoagulants; Cilostazol; Cytochrome P-450 CYP3A Inhibitors; Dideoxynucleo

2018
Effects of açaí and cilostazol on skin microcirculation and viability of TRAM flaps in hamsters.
    The Journal of surgical research, 2018, Volume: 228

    Topics: Animals; Capillaries; Cilostazol; Cricetinae; Disease Models, Animal; Drug Evaluation, Preclinical;

2018
Prognostic factors of ulcer healing and amputation-free survival in patients with critical limb ischemia.
    Vascular, 2018, Volume: 26, Issue:6

    Topics: Aged; Aged, 80 and over; Amputation, Surgical; Cilostazol; Critical Illness; Debridement; Disease-Fr

2018
Clinical ultrasound stimulating angiogenesis following drug-release from polymersomes on the ischemic zone for peripheral arterial occlusive disease.
    Nanomedicine : nanotechnology, biology, and medicine, 2018, Volume: 14, Issue:7

    Topics: Angiogenesis Inducing Agents; Animals; Arterial Occlusive Diseases; Bronchodilator Agents; Cilostazo

2018
Neuroprotective effects of cilostazol on retinal ganglion cell damage in diabetic rats.
    The Journal of pharmacology and experimental therapeutics, 2013, Volume: 345, Issue:3

    Topics: Animals; Apoptosis; Blood Glucose; Blotting, Western; Body Weight; Cell Death; Cilostazol; Diabetic

2013
Cilostazol improves the response to ischemia in diabetic mice by a mechanism dependent on PPARγ.
    Molecular and cellular endocrinology, 2013, Dec-05, Volume: 381, Issue:1-2

    Topics: Angiogenesis Inducing Agents; Animals; Cilostazol; Diabetes Mellitus, Experimental; Hindlimb; Ischem

2013
Levels and values of lipoprotein-associated phospholipase A2, galectin-3, RhoA/ROCK, and endothelial progenitor cells in critical limb ischemia: pharmaco-therapeutic role of cilostazol and clopidogrel combination therapy.
    Journal of translational medicine, 2014, Apr-17, Volume: 12

    Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Aged; Base Sequence; Cilostazol; Clopidogrel; DNA Pr

2014
Effects of ischemic preconditioning and cilostazol on muscle ischemia-reperfusion injury in rats.
    Acta cirurgica brasileira, 2014, Volume: 29 Suppl 3

    Topics: Animals; Cilostazol; Hindlimb; Ischemia; Ischemic Preconditioning; Male; Models, Animal; Muscle Fibe

2014
Cilostazol improves high glucose-induced impaired angiogenesis in human endothelial progenitor cells and vascular endothelial cells as well as enhances vasculoangiogenesis in hyperglycemic mice mediated by the adenosine monophosphate-activated protein kin
    Journal of vascular surgery, 2016, Volume: 63, Issue:4

    Topics: AMP-Activated Protein Kinases; Angiogenesis Inducing Agents; Animals; Cell Adhesion; Cell Movement;

2016
Combination of Cilostazol and L-Carnitine Improves Walking Performance in Peripheral Arterial Disease Model Rats.
    Pharmacology, 2015, Volume: 96, Issue:5-6

    Topics: Angiogenic Proteins; Animals; Carnitine; Cilostazol; Disease Models, Animal; Drug Therapy, Combinati

2015
Induction of Angiogenesis by a Type III Phosphodiesterase Inhibitor, Cilostazol, Through Activation of Peroxisome Proliferator-Activated Receptor-γ and cAMP Pathways in Vascular Cells.
    Arteriosclerosis, thrombosis, and vascular biology, 2016, Volume: 36, Issue:3

    Topics: Angiogenesis Inducing Agents; Angiopoietin-1; Animals; Capillaries; Cells, Cultured; Cilostazol; Cyc

2016
Cilostazol may improve outcome in critical limb ischemia.
    International angiology : a journal of the International Union of Angiology, 2009, Volume: 28, Issue:5

    Topics: Administration, Oral; Aged; Aged, 80 and over; Amputation, Surgical; Cilostazol; Critical Illness; F

2009
Cilostazol stimulates revascularisation in response to ischaemia via an eNOS-dependent mechanism.
    European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery, 2012, Volume: 43, Issue:1

    Topics: Angiogenesis Inducing Agents; Animals; Blotting, Western; Capillaries; Cilostazol; Disease Models, A

2012
Impact of cilostazol after endovascular treatment for infrainguinal disease in patients with critical limb ischemia.
    Journal of vascular surgery, 2011, Volume: 54, Issue:6

    Topics: Aged; Aged, 80 and over; Angioplasty, Balloon; Arterial Occlusive Diseases; Cilostazol; Female; Femo

2011
A novel vasculo-angiogenic effect of cilostazol mediated by cross-talk between multiple signalling pathways including the ERK/p38 MAPK signalling transduction cascade.
    Clinical science (London, England : 1979), 2012, Aug-01, Volume: 123, Issue:3

    Topics: Animals; Antigens, CD34; Apoptosis; Blood Vessels; Cell Movement; Cell Proliferation; Cilostazol; Co

2012
A novel vasculo-angiogenic effect of cilostazol mediated by cross-talk between multiple signalling pathways including the ERK/p38 MAPK signalling transduction cascade.
    Clinical science (London, England : 1979), 2012, Aug-01, Volume: 123, Issue:3

    Topics: Animals; Antigens, CD34; Apoptosis; Blood Vessels; Cell Movement; Cell Proliferation; Cilostazol; Co

2012
A novel vasculo-angiogenic effect of cilostazol mediated by cross-talk between multiple signalling pathways including the ERK/p38 MAPK signalling transduction cascade.
    Clinical science (London, England : 1979), 2012, Aug-01, Volume: 123, Issue:3

    Topics: Animals; Antigens, CD34; Apoptosis; Blood Vessels; Cell Movement; Cell Proliferation; Cilostazol; Co

2012
A novel vasculo-angiogenic effect of cilostazol mediated by cross-talk between multiple signalling pathways including the ERK/p38 MAPK signalling transduction cascade.
    Clinical science (London, England : 1979), 2012, Aug-01, Volume: 123, Issue:3

    Topics: Animals; Antigens, CD34; Apoptosis; Blood Vessels; Cell Movement; Cell Proliferation; Cilostazol; Co

2012
A novel vasculo-angiogenic effect of cilostazol mediated by cross-talk between multiple signalling pathways including the ERK/p38 MAPK signalling transduction cascade.
    Clinical science (London, England : 1979), 2012, Aug-01, Volume: 123, Issue:3

    Topics: Animals; Antigens, CD34; Apoptosis; Blood Vessels; Cell Movement; Cell Proliferation; Cilostazol; Co

2012
A novel vasculo-angiogenic effect of cilostazol mediated by cross-talk between multiple signalling pathways including the ERK/p38 MAPK signalling transduction cascade.
    Clinical science (London, England : 1979), 2012, Aug-01, Volume: 123, Issue:3

    Topics: Animals; Antigens, CD34; Apoptosis; Blood Vessels; Cell Movement; Cell Proliferation; Cilostazol; Co

2012
A novel vasculo-angiogenic effect of cilostazol mediated by cross-talk between multiple signalling pathways including the ERK/p38 MAPK signalling transduction cascade.
    Clinical science (London, England : 1979), 2012, Aug-01, Volume: 123, Issue:3

    Topics: Animals; Antigens, CD34; Apoptosis; Blood Vessels; Cell Movement; Cell Proliferation; Cilostazol; Co

2012
A novel vasculo-angiogenic effect of cilostazol mediated by cross-talk between multiple signalling pathways including the ERK/p38 MAPK signalling transduction cascade.
    Clinical science (London, England : 1979), 2012, Aug-01, Volume: 123, Issue:3

    Topics: Animals; Antigens, CD34; Apoptosis; Blood Vessels; Cell Movement; Cell Proliferation; Cilostazol; Co

2012
A novel vasculo-angiogenic effect of cilostazol mediated by cross-talk between multiple signalling pathways including the ERK/p38 MAPK signalling transduction cascade.
    Clinical science (London, England : 1979), 2012, Aug-01, Volume: 123, Issue:3

    Topics: Animals; Antigens, CD34; Apoptosis; Blood Vessels; Cell Movement; Cell Proliferation; Cilostazol; Co

2012
The protective effect of cilostazol on isolated rabbit femoral arteries under conditions of ischemia and reperfusion: the role of the nitric oxide pathway.
    Clinics (Sao Paulo, Brazil), 2012, Volume: 67, Issue:2

    Topics: Animals; Cilostazol; Disease Models, Animal; Femoral Artery; Hindlimb; Ischemia; Male; Nitric Oxide;

2012
Cilostazol promotes angiogenesis after peripheral ischemia through a VEGF-dependent mechanism.
    International journal of cardiology, 2013, Aug-10, Volume: 167, Issue:3

    Topics: Animals; Cilostazol; Disease Models, Animal; Hindlimb; Ischemia; Male; Mice; Mice, Inbred C57BL; Neo

2013
Cilostazol promotes angiogenesis after peripheral ischemia through a VEGF-dependent mechanism.
    International journal of cardiology, 2013, Aug-10, Volume: 167, Issue:3

    Topics: Animals; Cilostazol; Disease Models, Animal; Hindlimb; Ischemia; Male; Mice; Mice, Inbred C57BL; Neo

2013
Cilostazol promotes angiogenesis after peripheral ischemia through a VEGF-dependent mechanism.
    International journal of cardiology, 2013, Aug-10, Volume: 167, Issue:3

    Topics: Animals; Cilostazol; Disease Models, Animal; Hindlimb; Ischemia; Male; Mice; Mice, Inbred C57BL; Neo

2013
Cilostazol promotes angiogenesis after peripheral ischemia through a VEGF-dependent mechanism.
    International journal of cardiology, 2013, Aug-10, Volume: 167, Issue:3

    Topics: Animals; Cilostazol; Disease Models, Animal; Hindlimb; Ischemia; Male; Mice; Mice, Inbred C57BL; Neo

2013
Cilostazol promotes angiogenesis after peripheral ischemia through a VEGF-dependent mechanism.
    International journal of cardiology, 2013, Aug-10, Volume: 167, Issue:3

    Topics: Animals; Cilostazol; Disease Models, Animal; Hindlimb; Ischemia; Male; Mice; Mice, Inbred C57BL; Neo

2013
Cilostazol promotes angiogenesis after peripheral ischemia through a VEGF-dependent mechanism.
    International journal of cardiology, 2013, Aug-10, Volume: 167, Issue:3

    Topics: Animals; Cilostazol; Disease Models, Animal; Hindlimb; Ischemia; Male; Mice; Mice, Inbred C57BL; Neo

2013
Cilostazol promotes angiogenesis after peripheral ischemia through a VEGF-dependent mechanism.
    International journal of cardiology, 2013, Aug-10, Volume: 167, Issue:3

    Topics: Animals; Cilostazol; Disease Models, Animal; Hindlimb; Ischemia; Male; Mice; Mice, Inbred C57BL; Neo

2013
Cilostazol promotes angiogenesis after peripheral ischemia through a VEGF-dependent mechanism.
    International journal of cardiology, 2013, Aug-10, Volume: 167, Issue:3

    Topics: Animals; Cilostazol; Disease Models, Animal; Hindlimb; Ischemia; Male; Mice; Mice, Inbred C57BL; Neo

2013
Cilostazol promotes angiogenesis after peripheral ischemia through a VEGF-dependent mechanism.
    International journal of cardiology, 2013, Aug-10, Volume: 167, Issue:3

    Topics: Animals; Cilostazol; Disease Models, Animal; Hindlimb; Ischemia; Male; Mice; Mice, Inbred C57BL; Neo

2013
Effect of cilostazol and pentoxifylline on gait biomechanics in rats with ischemic left hindlimb.
    Journal of vascular surgery, 2012, Volume: 56, Issue:2

    Topics: Animals; Biomechanical Phenomena; Cilostazol; Gait; Hindlimb; Ischemia; Male; Pentoxifylline; Rats;

2012
Combination of cilostazol and clopidogrel attenuates rat critical limb ischemia.
    Journal of translational medicine, 2012, Aug-16, Volume: 10

    Topics: Animals; Blotting, Western; Cilostazol; Clopidogrel; Drug Therapy, Combination; Extremities; Flow Cy

2012
Impact of cilostazol on angiographic restenosis after balloon angioplasty for infrapopliteal artery disease in patients with critical limb ischemia.
    European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery, 2012, Volume: 44, Issue:6

    Topics: Aged; Aged, 80 and over; Angioplasty, Balloon; Cardiovascular Agents; Chi-Square Distribution; Cilos

2012
Effects of cilostazol in kidney and skeletal striated muscle of Wistar rats submitted to acute ischemia and reperfusion of hind limbs.
    Acta cirurgica brasileira, 2012, Volume: 27, Issue:11

    Topics: Animals; Apoptosis; Caspase 3; Cilostazol; Disease Models, Animal; Hindlimb; In Situ Nick-End Labeli

2012
Effect of cilostazol on impaired vasodilatory response of the brachial artery to ischemia in smokers.
    Journal of atherosclerosis and thrombosis, 2003, Volume: 10, Issue:2

    Topics: Adult; Arm; Brachial Artery; Cilostazol; Endothelium, Vascular; Humans; Hyperemia; Ischemia; Male; M

2003
Conservative regimen for chronic critical limb ischemia.
    Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 2004, Volume: 87, Issue:3

    Topics: Chi-Square Distribution; Cilostazol; Diet, Vegetarian; Exercise Therapy; Female; Humans; Ischemia; L

2004
Neuroprotective effect of cilostazol against retinal ischemic damage via inhibition of leukocyte-endothelial cell interactions.
    Journal of thrombosis and haemostasis : JTH, 2007, Volume: 5, Issue:4

    Topics: Animals; Blood Platelets; Cell Communication; Cilostazol; Endothelium, Vascular; Fibrinolytic Agents

2007
Three cases of digital ischemia successfully treated with cilostazol.
    Vascular medicine (London, England), 2001, Volume: 6, Issue:4

    Topics: Adult; Cilostazol; Fingers; Humans; Ischemia; Male; Middle Aged; Tetrazoles; Treatment Outcome; Vaso

2001